Catalyst Pharmaceuticals, Inc. (CPRX)
NEUTRALFondamental
72
Prix
$-
Capitalisation boursière
$3.85B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$597M
12 derniers mois (au 31/03/2026)
Résultat net
$221M
12 derniers mois (au 31/03/2026)
Flux de trésorerie libre
$172M
Capitaux propres totaux
$1.01B
Passif total
$3M
Ratio de liquidité général
7.10
Couverture des intérêts
-
Dette/EBITDA
0.01
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$47.09
Prix actuel
-
Marge de sécurité
-
Fourchette de juste valeur
$30.61 - $63.58
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
17.42
ROE
24.5%
Ratio P/B
3.80
P/FCF
-
Marge brute
86.0%
ROIC
20.8%
Radar de rentabilité
Value Creation (Economic Moat)
ROIC
20.8%
WACC
8.0%
ROIC − WACC
+12.8 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Critères d'analyse fondamentale
Réussi (16)
- ROIC 20.8%
- Gross Margin 86.0%
- Debt/Equity ratio
- Operating Margin 44.8%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 23.6%
- Revenue Growth 5Y 37.7%
- Earnings Surprise avg 13.8%
- PEG Ratio 0.92
- Earnings Quality (OCF/NI) 0.94
- Net Margin Trend 37.1% vs 36.9%
Échoué (4)
- P/B Ratio 3.80
- DCF valuation (Unknown)
- Analyst Consensus 0% Buy
- Piotroski F-Score 1/9
Indisponible (7)
- EPS data insufficient
- Historical price data insufficient
- P/FCF NaN
- Dividend Payout NaN%
- Interest Coverage
- Price below Graham Number
- Share Dilution (missing shares data)
Score F de Piotroski
Préoccupations financières sérieuses
Qualité des bénéfices
Modérée : certain écart entre profits et trésorerie
Dilution du capital
Rachat d'actions. Favorable aux actionnaires
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. Patrick J. McEnany | Co-Founder & Non-Executive Chairman | 78 |
| Mr. Richard John Daly M.B.A. | President, CEO & Director | 64 |
| Mr. Michael W. Kalb CPA | Executive VP, Treasurer & CFO | 54 |
| Dr. Steven R. Miller Ph.D. | Executive VP, COO & Chief Scientific Officer | 63 |
| Mr. Jeffrey Del Carmen | Executive VP & Chief Commercial Officer | 54 |
| Dr. William T. Andrews FACP, M.D. | Chief Medical Officer | 60 |
| Ms. Mary Coleman | VP & Head of Investor Relations | - |
| Mr. Brian Elsbernd J.D. | Chief Compliance Officer & Chief Legal Officer | 61 |
| Mr. Gregg Russo | Chief Human Resources Officer | 62 |
| Dr. Preethi Sundaram Ph.D. | Chief Strategy Officer | 49 |
Risque d'audit
8
Risque du conseil
3
Risque de rémunération
8
Risque droits des actionnaires
4
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Latest News
Recent headlines for CPRX, sourced from Markets Gazette.
- 4/27/2026POSITIVEItaly’s Angelini Said to Explore Acquisition of Catalyst Pharma
Catalyst Pharmaceuticals Inc. is reportedly being explored for acquisition by Italian drugmaker Angelini Pharma. This potential deal signals significant interest in Catalyst's assets and market position, suggesting a possible premium valuation for shareholders. Angelini Pharma's exploration indicates a strategic move to expand its global reach, potentially through acquiring Catalyst's product pipeline or market access. Investors will be watching for further developments, as an acquisition could lead to a substantial uplift in Catalyst's stock price.
- 4/27/2026NEUTRALItaly’s Angelini Said to Explore Catalyst Pharma Acquisition
Angelini Pharma, an Italian drugmaker, is reportedly exploring the acquisition of US-based Catalyst Pharmaceuticals Inc. This potential deal is part of Angelini's strategy to broaden its international presence. Catalyst Pharmaceuticals, trading on the Nasdaq, specializes in treatments for rare autoimmune diseases. While the exploration is in its early stages and no deal is guaranteed, the news highlights potential consolidation within the pharmaceutical sector. Investors will monitor developments for any concrete offers and the strategic rationale behind such a move.
via Markets Gazette